Form 4: GeneDx Holdings Director Reports Stock Transaction
Insider Transaction (Form 4)
Thomas Fuchs, a Director of GeneDx Holdings Corp., reported multiple transactions in common stock on September 17, 2026.
Summary
- Option exercise/conversion: acquired 1,146 Class A Common Stock on September 17, 2026; holds 1,146 after (Direct).
- Option exercise/conversion: disposed of 1,146 Restricted Stock Unit on September 17, 2026; holds 2,292 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Thomas Fuchs — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-17 | Option exercise/conversion | Class A Common Stock | 1,146 | — | — | 1,146 |
| 2026-09-17 | Option exercise/conversion | Restricted Stock Unit | 1,146 | — | — | 2,292 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-17 | Option exercise/conversion (1,146 shares) |
| 2026-09-17 | Option exercise/conversion (1,146 shares) |
Keywords
insider transaction, Form 4, WGS, GeneDx Holdings Corp., neutral, Thomas Fuchs
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.